Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

Abstract

Although BRAF^non-V600E mutations identified were a rare and unestablished molecular subtype, certain BRAF^non-V600E mutations might contribute to a lesser benefit of anti-EGFR monoclonal antibody treatment.